Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHINOOK THERAPEUTICS, INC.ADRO · Entity 110632 | Chief Medical Officer | September 12, 2018 | September 14, 2018 |
| Caribou Biosciences, Inc.CRBU · Entity 6445 | Director | February 20, 2026 | February 20, 2026 |
| Harpoon Therapeutics, Inc.HARP · Entity 11424 | Chief Medical Officer | January 28, 2022 | February 01, 2022 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 07, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | December 21, 2022 | December 23, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHINOOK THERAPEUTICS, INC.
Report date September 12, 2018 · Filed September 14, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,720 |
Ending reported balance
After 2018-09-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2018-09-12 · Grant · Acquired 87,200 · Balance 176,748 F1: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018. Row 2 · 2018-09-13 · Sale · Disposed 3,028 · Balance 173,720 F2: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018.
F2: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Caribou Biosciences, Inc.
Report date February 20, 2026 · Filed February 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $1.80 · Expires 2036-02-19 | Direct | 45,000 |
Reported balance
After 2026-02-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-20 · Grant · Acquired 45,000 · Balance 45,000 F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.
Harpoon Therapeutics, Inc.
Report date January 28, 2022 · Filed February 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.03 · Expires 2032-01-27 | Direct | 155,000 |
Reported balance
After 2022-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-01-28 · Grant · Acquired 155,000 · Balance 155,000 F1: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the total stock option will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 28, 2022, subject to the continuing employment of the Reporting Person on each vesting date.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date December 21, 2022 · Filed December 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.75 · Expires 2032-12-20 | Direct | 25,000 |
Reported balance
After 2022-12-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-12-21 · Grant · Acquired 25,000 · Balance 25,000 F1: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of December 21, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 16, 2020 Filed Jan 21, 2020 20:05 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1,521 | $2.12 | $3,224.52 |
DisclosureSEC source: 0001209191-20-004374 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,826 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-20-002179 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,230 Underlying: Common Stock · 5,826 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,826 | $14.18 | $82,600.45 |
DisclosureSEC source: 0001209191-20-002179 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $14.0455 to $14.55 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:46 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 5,826 | $2.12 | $12,351.12 |
DisclosureSEC source: 0001209191-20-002179 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 1,521 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-061097 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,231 Underlying: Common Stock · 1,521 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,521 | $17.02 | $25,887.57 |
DisclosureSEC source: 0001209191-19-061097 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $17.01 to $17.35 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 16:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 1,521 | $2.12 | $3,224.52 |
DisclosureSEC source: 0001209191-19-061097 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:42 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,826 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-059085 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 198,056 Underlying: Common Stock · 5,826 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:42 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,826 | $17.98 | $104,751.48 |
DisclosureSEC source: 0001209191-19-059085 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 16:42 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 5,826 | $2.12 | $12,351.12 |
DisclosureSEC source: 0001209191-19-059085 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 16:24 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,252 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-057167 · doc4.xml · derivative · entry 4 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,752 Underlying: Common Stock · 18,252 shares Expires 2028-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on November 16, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 16:24 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 1,000 | $14.00 | $14,000.00 |
DisclosureSEC source: 0001209191-19-057167 · doc4.xml · nonDerivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 16:24 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 17,252 | $13.33 | $229,963.98 |
DisclosureSEC source: 0001209191-19-057167 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $13.00 to $13.95 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 16:24 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 18,252 | $2.12 | $38,694.24 |
DisclosureSEC source: 0001209191-19-057167 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,006 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 5,826 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-055169 · doc4.xml · derivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,882 Underlying: Common Stock · 5,826 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 5,826 | $13.17 | $76,701.62 |
DisclosureSEC source: 0001209191-19-055169 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $13.00 to $13.3822 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 16:09 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 5,826 | $2.12 | $12,351.12 |
DisclosureSEC source: 0001209191-19-055169 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 11,698 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-053306 · doc4.xml · derivative · entry 6 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,708 Underlying: Common Stock · 11,698 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 11,698 | $13.21 | $154,481.45 |
DisclosureSEC source: 0001209191-19-053306 · doc4.xml · nonDerivative · entry 4 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $13.01 to $13.39 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 11,698 | $2.12 | $24,799.76 |
DisclosureSEC source: 0001209191-19-053306 · doc4.xml · nonDerivative · entry 3 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,452 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 12,452 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001209191-19-053306 · doc4.xml · derivative · entry 5 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,406 Underlying: Common Stock · 12,452 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 1, 2019, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | SaleCommon Stock | 12,452 | $13.27 | $165,280.38 |
DisclosureSEC source: 0001209191-19-053306 · doc4.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,754 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $13.00 to $13.77 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 17:14 UTC | Harpoon Therapeutics, Inc. HARP · Entity 11424 | Exercise / conversionCommon Stock | 12,452 | $2.12 | $26,398.24 |
DisclosureSEC source: 0001209191-19-053306 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 06, 2019 Filed May 8, 2019 16:26 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.11 | $0.00 |
DisclosureSEC source: 0000899243-19-012639 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Shares · 10,000 shares Expires 2029-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2019. Read SEC document |
| September 13, 2018 Filed Sep 14, 2018 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 3,028 | $6.50 | $19,679.88 |
DisclosureSEC source: 0001567619-18-002681 · doc1.xml · nonDerivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,720 F2 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 12, 2018 Filed Sep 14, 2018 19:25 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 87,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-18-002681 · doc1.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,748 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2018. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 19:40 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 4,504 | $7.13 | $32,099.11 |
DisclosureSEC source: 0001567619-18-002235 · doc1.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,548 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.05 to $7.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 08, 2018 Filed Feb 12, 2018 20:20 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 174,400 | $0.00 Strike: $6.05 | $0.00 |
DisclosureSEC source: 0001209191-18-009387 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,400 Underlying: Common Stock · 174,400 shares Expires 2028-02-07 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of February 8, 2018. Read SEC document |
| December 11, 2017 Filed Dec 13, 2017 20:19 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 16,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-065523 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,052 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of December 11, 2017. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 21:23 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 32,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-052895 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,740 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the grant date of September 12, 2017. Read SEC document |
| September 01, 2017 Filed Sep 6, 2017 16:32 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | SaleCommon Stock | 4,885 | $11.71 | $57,196.02 |
DisclosureSEC source: 0001209191-17-051631 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,115 F1 · kind: The shares were sold to cover the tax obligation that occurred upon the vesting of an RSU. Read SEC document |
| June 12, 2017 Filed Jun 14, 2017 21:15 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantStock Option (right to buy) · Derivative | 32,625 | $0.00 Strike: $10.75 | $0.00 |
DisclosureSEC source: 0001209191-17-040000 · doc4.xml · derivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,625 Underlying: Common Stock · 32,625 shares Expires 2027-06-11 F1 · derivative.exercise_date: The shares subject to the Option vest in 48 equal monthly installments from the vesting commencement date of June 12, 2017. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 16:22 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantEmployee Stock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0001209191-16-141404 · doc4.xml · derivative · entry 2 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2026-09-11 F2 · derivative.exercise_date: The shares subject to the Option vest over a four-year period as follows: 25% of the shares vest on the one year anniversary of the vesting commencement date of August 31, 2016 and thereafter the remaining shares vest in a series of equal monthly installments at a rate of one thirty-sixth (1/36th) per month. Read SEC document |
| September 12, 2016 Filed Sep 14, 2016 16:22 UTC | CHINOOK THERAPEUTICS, INC. ADRO · Entity 110632 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-141404 · doc4.xml · nonDerivative · entry 1 Sacks Natalie · CIK 0001683811 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents grant of restricted stock units payable in common stock that vest in four equal annual installments from the vesting commencement date of August 31, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.